New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperformance, warranty expiry, and asset transactionsTEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that its DeepSolar business unit has launched Smart TDD, an advanced solar Technical Due Diligence (“TDD”) service designed to provide faster, more accurate, and more co ...

Summary of Flux Power Holdings Inc. Conference Call Company Overview - **Company Name**: Flux Power Holdings Inc. - **Industry**: Lithium-ion battery manufacturing - **Location**: Vista, California - **Products**: Lithium-ion battery packs, energy management systems, cloud-based SaaS platform for battery monitoring and control [2][3] Core Business Segments - **Material Handling**: Primarily used in forklifts across warehouses - **Airport Ground Support Equipment (GSE)**: Powers vehicles like tugs and pushback trucks at airports [3] Strategic Vision - Transition customers from lead-acid to lithium-ion batteries for improved productivity and ROI - Focus on operational efficiencies and profitability through new leadership and strategic objectives [4][7] Leadership Changes - New leadership team introduced to drive growth and profitability - Key members include: - **Krishna Vanka**: CEO with experience in battery and charging infrastructure - **Kevin Royal**: CFO with extensive experience in publicly traded companies - **Kelly Frey**: Chief Revenue Officer focusing on customer engagement and sales [4][6][7] Financial Performance - Revenue has stagnated between $60-$67 million over the last three years - Break-even point estimated at $16 million in revenue - Recent quarter saw a decline to $13.2 million due to tariffs impacting customer orders [20][21] Market Opportunity - **Material Handling Battery Market**: Estimated at $2.5 billion in 2025, growing at 9% - **GSE Market**: Projected to be a $5 billion business in the next year, growing at 7.8% - Current lithium-ion adoption in the forklift industry is only 15%-20%, indicating significant growth potential [15][17][16] Product Development and Innovation - Focus on modular product design to enhance scalability and efficiency - Recent patents awarded for AI-driven energy optimization and advanced battery management systems [13][14] - Introduction of intelligent batteries with remote monitoring capabilities [10][14] Customer Segments - Diverse applications across industries including food and beverage, retail, manufacturing, and airport GSE - Notable customers include major airlines and companies like Amazon and Caterpillar [18] Challenges and Future Outlook - Impact of tariffs has created uncertainty in order cadence, but signs of normalization are emerging - Plans to enhance gross margins through supply chain improvements and product redesign [21][24] - Anticipation of increased demand as customers transition to lithium-ion solutions [23][26] Conclusion - Flux Power is positioned for growth in the lithium-ion battery market with a strong focus on operational efficiency and customer engagement - The leadership team is committed to achieving profitability and capitalizing on the growing market demand for lithium-ion solutions [32]

Core Viewpoint - PainReform Ltd. has initiated a development plan for OcuRing™-K, a patented sustained-release ocular therapy aimed at improving postoperative care in cataract surgery, targeting a significant market opportunity in the multi-billion-dollar global cataract surgery market [1][5]. Company Overview - PainReform Ltd. focuses on reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform, reflecting a strategic commitment to applying precision technology across healthcare and sustainable energy sectors [10]. Product Development - OcuRing-K is designed as an erodible, intraoperatively administered device that provides sustained-release of ketorolac, addressing the limitations of traditional eye-drop regimens that often deliver less than 5% of the drug to the target site [2][3]. - The development plan for OcuRing-K includes progressing towards a Phase II clinical trial, with a focus on post-cataract pain and inflammation as the initial target indication [1][7]. Clinical and Market Context - Cataract surgery is a prevalent procedure, with approximately 4.5 million surgeries performed annually in the U.S. and a global surgical procedure volume exceeding $9 billion [5]. - Current postoperative management relies heavily on multi-week corticosteroid and NSAID eye-drop regimens, which are burdensome for elderly patients and often inconsistently delivered [5]. Technological Advantages - OcuRing-K's in-situ depot formulation allows for direct, localized delivery to target tissues, providing controlled and stable therapeutic coverage while reducing systemic exposure and contamination risks associated with traditional drops [3][4]. - Preclinical studies and Phase I evaluations have shown that OcuRing-K can reduce post-surgical pain and inflammation with lower total drug exposure compared to standard regimens, enhancing patient compliance [4]. Future Plans - PainReform and LayerBio plan to advance OcuRing-K through its next stage of clinical development in the U.S., which could unlock a high-volume reimbursable market and enable expansion into additional ophthalmic indications [7].

Core Insights - PainReform Ltd. has made significant advancements in both specialty pharmaceuticals and renewable energy technologies during the first half of 2025, focusing on non-opioid solutions for pain management and AI-driven solar analytics [3][12] Pharmaceutical Programs - The company acquired a majority interest in LayerBio, enhancing its pipeline with the OcuRing™-K platform, a novel therapy targeting a global market of approximately $9 billion for post-surgical pain management [6][7] - Continued development of PRF-110 is underway, which showed significant efficacy in the early postoperative period despite not meeting primary endpoints in a Phase 3 trial [7] DeepSolar Division - The DeepSolar division has shown strong momentum, highlighted by the completion of the MyDeepSolar consumer app and acceptance into NVIDIA's Connect Program, which will aid in developing the DeepSolar Predict forecasting solution [3][14] - A successful 92MW pilot project with Econergy in Romania has transitioned into the company's first commercial customer agreement, marking a significant step in commercial deployment [3][14] Financial Performance - The company reduced its net loss to approximately $2.3 million for the six months ended June 30, 2025, down from $12.8 million in the same period the previous year [11] - Research and development expenses significantly decreased to approximately $0.3 million compared to $11.4 million in the prior year, primarily due to the completion of the Phase 3 clinical trial for PRF-110 [9] - As of June 30, 2025, PainReform maintained cash and cash equivalents of approximately $3.5 million and positive working capital of approximately $1.5 million [11]